M&A Deal Summary |
|
|---|---|
| Date | 2012-04-30 |
| Target | EUSA Pharma |
| Sector | Life Science |
| Buyer(s) | Jazz Pharmaceuticals |
| Sellers(s) | EW Healthcare Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 680M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2003 |
| Sector | Life Science |
| Employees | 2,800 |
| Revenue | 3.8B USD (2023) |
Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops, and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 6 |
| Sector (Life Science) | 2 of 6 |
| Type (Add-on Acquisition) | 2 of 6 |
| State (Pennsylvania) | 1 of 1 |
| Country (United States) | 2 of 4 |
| Year (2012) | 1 of 1 |
| Size (of disclosed) | 4 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-04-19 |
Orphan Medical
Minnetonka, Minnesota, United States Orphan Medical is a specialty pharmaceutical company which acquires, develops, and markets pharmaceuticals for inadequately treated and uncommon diseases, including sleep disorders. The Company recently received regulatory approval in the United States for Xyrem, a therapeutic for the treatment of cataplexy. Orphan Medical was a public company traded on Nasdaq under the symbol ORPH. |
Buy | $123M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-20 |
Gentium
Villa Guardia, Italy Gentium S.p.A. (GENT) specializes in potential therapeutic agents, the active ingredients of which are derived from natural sources. They are developing Defibrotide for severe Hepatic Veno-Occlusive Disease (VOD), a potential complication of stem cell transplantation. Their other products include heparin calcium and urokinase. |
Buy | $1.0B |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
| DEAL STATS | # |
|---|---|
| Overall | 28 of 53 |
| Sector (Life Science) | 11 of 17 |
| Type (Add-on Acquisition) | 18 of 34 |
| State (Pennsylvania) | 6 of 7 |
| Country (United States) | 24 of 46 |
| Year (2012) | 1 of 3 |
| Size (of disclosed) | 2 of 22 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-01-31 |
Grupo Farmaceutico Biotoscana S.A.
Montevideo, Uruguay Grupo Farmaceutico Biotoscana S.A. is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation, and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, and LKM. Biotoscana was formed in 1994 and is based in Montevideo, Uruguay. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-05-01 |
PreCision Dermatology
Cumberland, Rhode Island, United States PreCision Dermatology, Inc. is a specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products. Our mission is to develop innovative skincare therapies with proven clinical performance that patients prefer and physicians are confident to prescribe. |
Sell | $85M |
